Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million. Pfizer led the extension with an investment through its Pfizer Breakthrough Growth Initiative, which provides funding and access to Pfizer’s scientific expertise to support biotechnology companies’ most promising clinical development programs. Walleye Capital and Asabys Partners, CatalobiaBio & HealthTech members, also participated in the extension as new Agomab investors, along with existing investors.
"With this investment, we are continuing our commitment to the products initially developed at Origo Biopharma. Agomab is a highly competitive European company with a complementary pipeline in the field of fibrosis and tissue regeneration. The entry of Pfizer as a shareholder corroborates the pharma's interest in these therapeutic areas," adds Clara Campàs, Managing Partner of Asabys Partners.
The additional funds will allow Agomab to advance the clinical trials of its most advanced product (AGMB-129) and to develop two of its pre-clinical programmes to the clinic in the coming months.
Photo: Clara Campàs
Comments